Anti-VEGF therapy for choroidal neovascularisation previously treated with photodynamic therapy

Eye

Volumn 24, Issue 6, 2010, Pages 1018-1023

  Jyothi, S ^a   Chowdhury, H R ^a   Chong, V ^a   Sivaprasad, S ^a  

^a Department of Ophthalmology   (United States)

Author keywords

Anti VEGF; Bevacizumab; Choroidal neovascularisation; Photodynamic therapy; Ranibizumab

Indexed keywords

BEVACIZUMAB; OFLOXACIN; RANIBIZUMAB; VERTEPORFIN;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; MALE; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; TREATMENT OUTCOME; VISION; VISUAL ACUITY;

EID: 77953584058     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2009.266     Document Type: Article

References (16)

1. Macular Photocoagulation Study Group. Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the Macular Photocoagulation Study. Arch Ophthalmol 1991; 109: 1242-1257.
2. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Arch Ophthalmol 1999; 117: 1329-1345.
3. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina 2005; 25(2): 111-118.
4. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431.
5. Brown DM, Kaiser PK, Michels M, Heier JS, Sy JP, Ianchulev T et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444.
6. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009; 116(1): 57-65.e5.
7. Spaide RF, Laud K, Fine HF, Klancnik Jr JM, Meyerle CB, Yannuzzi LA et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006; 26: 383-390. (Pubitemid 44197628)
8. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer W et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143(4): 566-583.
9. Arias L, Caminal JM, Casas L, Masuet C, Badia MB, Rubio M et al. A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular agerelated macular degeneration. Br J Ophthalmol 2008; 92(12): 1636-1641.
10. Antoszyk AN, Tuomi L, Chung CY, Singh A, FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 2008; 145(5): 862-874.
11. Michels S, Schmidt-Erfurth U. Sequence of early vascular events after photodynamic therapy. Invest Ophthalmol Vis Sci 2003; 44(5): 2147-2154.
12. Sivaprasad S, Saleh GM, Jackson H. Does lesion size determine the success rate of photodynamic therapy for age-related macular degeneration? Eye 2006; 20(1): 43-45.
13. Patel PJ, Browning AC, Chen FK, Da Cruz L, Tufail A. Interobserver agreement for the detection of optical coherence tomography features of neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2009, e-pub ahead of print 24 June 2009.
14. Kumar A, Gopalakrishnan K, Sinha S. Combination photodynamic therapy and intravitreal ranibizumab in neovascular age-related macular degeneration in a North Indian population: a pilot study. Retina 2008; 28(9): 1296-1301.
15. Zuluaga MF, Mailhos C, Robinson G, Shima DT, Gurny R, Lange N. Synergies of VEGF inhibition and photodynamic therapy in the treatment of age-related macular degeneration. Invest Ophthalmol Vis Sci 2007; 48(4): 1767-1772.
16. Ju M, Mailhos C, Bradley J, Dowie T, Ganley M, Cook G et al. Simultaneous but not prior inhibition of VEGF165 enhances the efficacy of photodynamic therapy in multiple models of ocular neovascularization. Invest Ophthalmol Vis Sci 2008; 49(2): 662-670.